1. Induced Disease Models Products Neuronal Signaling
  2. Nervous System Disease Models Amyloid-β
  3. β-Amyloid (1-42), human, HFIP-treated

β-Amyloid (1-42), human, HFIP-treated 

Cat. No.: HY-P1363B Purity: 98.41%
Handling Instructions Technical Support

β-Amyloid (1-42), human, HFIP-treated, a 42-amino acid peptide that has been treated with HFIP from β-Amyloid (1-42), human (HY-P1363A), is a brain-penetrant amyloid protein fragment, which can be used in research on Alzheimer's disease and Down’s syndrome. β-Amyloid (1-42), human, HFIP-treated remaining as a monomer exhibits antioxidant and neuroprotective effects. β-Amyloid (1-42), human, HFIP-treated, after being dissolved in DMSO to form the stock solution, on the one hand, can form soluble oligomers (AβOs) when incubated at 4°C, which have synaptic toxicity and neurotoxicity; on the other hand, it can be incubated at 37°C to form insoluble fibrils, with lower neurotoxicity, and participating in the oxidative damage process. Aβ42 oligomers bind to various neuronal surface receptors (such as PrPc, mGluR5, NMDA receptors, etc.), triggering oxidative stress, calcium homeostasis imbalance, and synaptic toxicity via activating downstream signaling pathways, leading to neuronal dysfunction and death.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

CAS No. : 107761-42-2

Size Price Stock Quantity
1 mg In-stock
5 mg (1 mg * 5) In-stock
10 mg (1 mg * 10) Get quote

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 24 publication(s) in Google Scholar

Other Forms of β-Amyloid (1-42), human, HFIP-treated:

Top Publications Citing Use of Products

    β-Amyloid (1-42), human, HFIP-treated purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2024 Dec 23;21(1):327.  [Abstract]

    Protein levels in BV2 cell treated with or without BCAAs/ BCKAs for 4 h in the presence of Aβ (1 μM) and the corresponding quantification results (n = 3).

    β-Amyloid (1-42), human, HFIP-treated purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2024 Jul 24:178:117199.  [Abstract]

    The effect of NMN on the survival rate of β-Amyloid (1-42) (Aβ, 1 μM; 24 h)-induced PC12 cells was determined by MTT assay.

    β-Amyloid (1-42), human, HFIP-treated purchased from MedChemExpress. Usage Cited in: Front Aging Neurosci. 2022 Apr 25;14:890134.  [Abstract]

    Immunofluorescence showed lost ARC expression after 10 μM Aβ treatment. For Aβ treatment, human β-Amyloid (1-42) (HY-P1363) was dissolved, and the solution was incubated for 3 days at 37°C to form oligomeric Aβ, and then cells were treated with 10 μM for 48 h.

    β-Amyloid (1-42), human, HFIP-treated purchased from MedChemExpress. Usage Cited in: Front Aging Neurosci. 2022 Apr 25;14:890134.  [Abstract]

    qRT-PCR showed decreased mRNA levels of ARC after 10 μM Aβ treatment (n = 3). For Aβ treatment, human β-Amyloid (1-42) (HY-P1363) was dissolved, and the solution was incubated for 3 days at 37°C to form oligomeric Aβ, and then cells were treated with 10 μM for 48 h.

    β-Amyloid (1-42), human, HFIP-treated purchased from MedChemExpress. Usage Cited in: Front Aging Neurosci. 2022 Apr 25;14:890134.  [Abstract]

    Western blotting analysis showed declined protein levels of ARC after 10 μM Aβ treatment (n = 3). For Aβ treatment, human β-Amyloid (1-42) (HY-P1363) was dissolved, and the solution was incubated for 3 days at 37°C to form oligomeric Aβ, and then cells were treated with 10 μM for 48 h.

    β-Amyloid (1-42), human, HFIP-treated purchased from MedChemExpress. Usage Cited in: Aging. 2021 Jun 9;13(11):15569-15579.  [Abstract]

    10 μM Aβ increased the mRNA expression of GRIA1 and GRIN2A, and decreased GRIN1 mRNA expression. n = 3. For the Aβ treatment, cells were incubated with 10 μM human β-Amyloid (1-42) for 48 h.
    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    β-Amyloid (1-42), human, HFIP-treated, a 42-amino acid peptide that has been treated with HFIP from β-Amyloid (1-42), human (HY-P1363A), is a brain-penetrant amyloid protein fragment, which can be used in research on Alzheimer's disease and Down’s syndrome. β-Amyloid (1-42), human, HFIP-treated remaining as a monomer exhibits antioxidant and neuroprotective effects. β-Amyloid (1-42), human, HFIP-treated, after being dissolved in DMSO to form the stock solution, on the one hand, can form soluble oligomers (AβOs) when incubated at 4°C, which have synaptic toxicity and neurotoxicity; on the other hand, it can be incubated at 37°C to form insoluble fibrils, with lower neurotoxicity, and participating in the oxidative damage process. Aβ42 oligomers bind to various neuronal surface receptors (such as PrPc, mGluR5, NMDA receptors, etc.), triggering oxidative stress, calcium homeostasis imbalance, and synaptic toxicity via activating downstream signaling pathways, leading to neuronal dysfunction and death[1][2][3][4][5][6][7].

    In Vitro

    β-Amyloid Aggregation Guidelines (Following is our recommended protocol. This protocol only provides a guideline, and should be modified according to your specific needs of your downstream experimental schemes). Oligomer preparation
    1. β-Amyloid (1-42), human, treated with HFIP is dissolved in anhydrous DMSO/0.1M NaOH/1% ammonia solution at 5 mM. Then, dilute it with sterile double-distilled water to a certain concentration (eg: 200 μM) to ensure complete dissolution.
    2. Next, the solution is age 24-48 h at 4-8°C. The sample is then centrifuged at 14000g for 10 min at 4-8°C; the soluble oligomers are in the supernatant. The supernatant is diluted 10-200-fold for experiments.
    Fiber preparation:
    1. β-Amyloid (1-42), human, treated with HFIP is dissolved in anhydrous DMSO at 5 mM and then dilutes into the appropriate concentration and buffer (10 mM HCl) with vortexing.
    2. Next, the solution is age 24-48 h at 37°C to obtain Aβ42 fibrils.
    Note:
    1) If using PBS for dilution, it may cause the precipitation of the polypeptide.
    2) The aggregation form is unstable in the solution, it is recommended to prepare and use it immediately. If storage is required, it is recommended to store the peptides in a film form at -20°C or -80°C.

    β-Amyloid (1-42), human, HFIP-treated is prepared into oligomers, exhibiting neurotoxicity:
    β-amyloid (1–42) peptide (60-180 μM, 48 h) could form oligomers significantly faster than Aβ40 and Aβ43 and Aβ42 oligomers (1-1000 μg/mL, 48 h) showed the greatest level of neurotoxicity in both SH-SY5Y and PC12 cells[10].
    Aβ42 oligomers (20 μM, 0-48 h) induces both apoptosis and autophagy in SH-SY5Y cells but only autophagy in U87 cells[11].
    Aβ42 oligomers (0.5 μM, 1 h) induces intracellular Ca2+ influx, mitochondrial reactive oxygen species (ROS) production and increases cell death in mouse neuroblastoma N2a cells[12].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    In Vivo

    Note:
    Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Molecular Weight

    4514.04

    Formula

    C203H311N55O60S

    CAS No.
    Appearance

    Film

    Sequence

    Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-Ile-Ala

    Sequence Shortening

    DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA

    Shipping

    Shipping with dry ice.

    Storage

    Please store the product under the recommended conditions in the Certificate of Analysis.

    Solvent & Solubility
    In Vitro: 

    DMSO : 200 mg/mL (44.31 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 0.2215 mL 1.1077 mL 2.2153 mL
    5 mM 0.0443 mL 0.2215 mL 0.4431 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    Purity & Documentation

    Purity: 99.89%

    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 0.2215 mL 1.1077 mL 2.2153 mL 5.5383 mL
    5 mM 0.0443 mL 0.2215 mL 0.4431 mL 1.1077 mL
    10 mM 0.0222 mL 0.1108 mL 0.2215 mL 0.5538 mL
    15 mM 0.0148 mL 0.0738 mL 0.1477 mL 0.3692 mL
    20 mM 0.0111 mL 0.0554 mL 0.1108 mL 0.2769 mL
    25 mM 0.0089 mL 0.0443 mL 0.0886 mL 0.2215 mL
    30 mM 0.0074 mL 0.0369 mL 0.0738 mL 0.1846 mL
    40 mM 0.0055 mL 0.0277 mL 0.0554 mL 0.1385 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Requested Quantity *

    Applicant Name *

     

    Salutation

    Email Address *

     

    Phone Number *

    Department

     

    Organization Name *

    City

    State

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    β-Amyloid (1-42), human, HFIP-treated
    Cat. No.:
    HY-P1363B
    Quantity:
    MCE Japan Authorized Agent: